Research brief · for a medical researcher
Not a claim that oncology guidelines already list these as cures. A compact set of primary papers, trials, and reviews showing multi-target anti-cancer activity — and where human data exists — so you can open the sources yourself.
Evidence is tiered so preclinical mass is not confused with Phase 3 proof.
The honest framing: There is a large, peer-reviewed literature showing these agents hit oncogenic pathways (microtubules, PAK1, Wnt/β-catenin, glycolysis, cancer stem cells, MDR pumps) across many tumor types. Mebendazole has the most formal neuro-oncology trial activity. Ivermectin has active immuno-oncology combination trials. Fenbendazole has strong lab/animal data and patient lore, but thin controlled human data. None of the three are FDA-approved for cancer as of mid-2026.
Highest signal density for a trained reader. Each link is primary or registry.
Best single extensive review of MBZ anticancer data.
Foundational repositioning review of mechanisms and models.
PK + anticancer biology; calls for clinical testing.
Safe/tolerated to 200 mg/kg/day in high-grade glioma.
“Cold→hot” tumors; basis for TNBC combination trials.
Self-reported outcomes; read methods critically (see Human data).
This is the section that matters most if the claim is about patients, not petri dishes.
NCT05318469
NCT07487805
NCT01837862
NCT01729260
Krystal et al., Pediatr Blood Cancer 2024. MBZ with bevacizumab and irinotecan was safe and well tolerated up to 200 mg/kg/day. Efficacy needs further study — but this is formal human oncology trial data, not social media.
Hulscher, McCullough, Risch, et al., Anticancer Research 2026. Prospective telemedicine program: N=197 enrolled, 122 completed ~6-month survey. Self-reported clinical benefit 84.4%; regression 15.6%; NED 32.8%. Authors flag observational design, self-report, concurrent conventional therapy, and selection bias. Treat as hypothesis-generating — open the methods before the headline number.
| Source | |
|---|---|
| PubMed abstract Anticancer Res. 2026;46(6):3243-3255 | 2026 |
| Full text (IIAR) | |
| Zenodo preprint / PDF |
ISOM / hybrid orthomolecular protocol (Sept 2024): IVM + benzimidazoles + metabolic stack (vitamins, keto/fasting, methylene blue, etc.). Peer-reviewed protocol framework widely shared online — useful as a design document, not proof of cure rates.
| Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol | 2024 |
Human antiparasitic (FDA-approved for parasites). Extensive preclinical oncology literature; active ICI combination trials.
Mechanisms often reported: PAK1 inhibition · Wnt/β-catenin · importin α/β nuclear transport · Akt/mTOR · YAP1 · mitochondrial stress · MDR/P-gp reversal · immune “cold→hot” conversion with checkpoint blockade
Hundreds of related PMIDs (mixed quality — includes some non-oncology hits):
Human antiparasitic. Strongest formal oncology trial footprint of the three — especially brain tumors (Johns Hopkins lineage).
Mechanisms often reported: microtubule destabilization · anti-angiogenesis · cancer stemness / metastasis · STAT3 · radiosensitization · multi-pathway chemo-sensitization
Veterinary benzimidazole. Strong cell/animal signal; human data mostly cases/anecdotes. Bioavailability and hepatotoxicity matter — see safety row.
Mechanisms often reported: microtubule disruption · p53 · GLUT1 / hexokinase / glycolysis block · proteasome impairment · pyroptosis (HK2/GSDME) · cancer stem cells
“Signal” means published work exists — not that guidelines recommend the agent.
| Cancer | Agents with published signals | Human-data note |
|---|---|---|
| Glioblastoma / HGG | MBZ (strongest path), IVM, benzimidazoles | MBZ Phase 1 combos published |
| Breast / TNBC | IVM (+ ICI), MBZ, FBZ | IVM + checkpoint trials active |
| Prostate | IVM, MBZ (+ docetaxel), FBZ | Large share of 2026 observational cohort |
| Ovarian | IVM, MBZ, FBZ | Mostly preclinical |
| Pancreatic | IVM (+ gemcitabine), MBZ | Mostly preclinical |
| Colorectal / GI | IVM, MBZ, FBZ family | MBZ Phase 2a GI |
| Lung / NSCLC | IVM, MBZ, FBZ | FBZ hepatotoxicity case report |
| Melanoma | IVM, MBZ, flubendazole | Case-series claims online (verify status) |
| HCC / liver | IVM (+ sorafenib), FBZ, MBZ | Preclinical dominant |
| Leukemia / myeloma | IVM, MBZ | Preclinical / differentiation screens |
A serious researcher will want the counterweight. These are not “debunkings of mechanisms” — they track the clinical-evidence gap.
Against off-trial use; lists known trials (TNBC, ICONIC). Evidence-gap framing.
Evidence ladder: lab → animals → rigorous human trials.
Large PubMed aggregation for IVM, FBZ, MBZ, methylene blue, HCQ.
Live search of registered studies.
Separate page: published complete remissions, cell therapies, mRNA vaccines, and company approvals (not antiparasitics).